GAD1

The GAD1 gene encodes glutamate decarboxylase 67 (GAD67), the main enzyme responsible for producing gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. 

Impaired GAD1 function has been linked to a range of neurological and psychiatric disorders, including developmental epileptic encephalopathies, schizophrenia, and anxiety-related conditions due to disrupted inhibitory signaling.

What is GAD1 (Glutamate Decarboxylase 1)?

The GAD1 gene encodes glutamate decarboxylase 67 (GAD67), the primary enzyme responsible for synthesizing gamma-aminobutyric acid (GABA), the brain's major inhibitory neurotransmitter. 

GAD67 catalyzes the conversion of glutamate (an excitatory neurotransmitter) into GABA, helping to regulate neuronal excitability and maintain balance in the brain's signaling systems.

Glutamate decarboxylases (GADs) are vitamin B6-dependent enzymes that require pyridoxal-5′-phosphate (PLP), the active form of vitamin B6, as a cofactor for converting glutamate into GABA.

The GAD1 gene is also expressed as the mRNA transcript GAD25, although GAD67 is this enzyme's major enzymatically active version.

GAD1: The Gene Encoding GAD67

GAD1 is highly expressed in GABAergic neurons throughout the brain, including the prefrontal cortex, hippocampus, and cerebellum. It is essential for inhibitory neurotransmission, which influences cognition, mood, sleep, and seizure control. 

GAD1 contributes to the majority of brain GABA synthesis, while its paralog, GAD2 (GAD65), covers the remaining portion.

GABA Synthesis and Neurotransmission

GAD67 produces baseline (non-synaptic) GABA to maintain a steady inhibitory tone. GABAergic neurotransmission is necessary for modulating excitatory signals, preventing overstimulation, and regulating key functions such as anxiety, working memory, and sleep.

GAD1 expression develops progressively, increasing from the prenatal stage into adolescence, coinciding with critical periods for brain maturation and synaptic plasticity.

GAD1 and Development

GAD1 expression is tightly regulated during development, steadily increasing from prenatal life through adolescence.

What Do Specific GAD1 Variants Mean?

Research suggests that certain GAD1 variants may:

• Lead to reduced GABA synthesis.
• Increase vulnerability to schizophrenia, epilepsy, and neurodevelopmental disorders.
• Alter the regulation of inhibitory-excitatory balance during critical stages of brain development.

These effects are often mediated by epigenetic changes (e.g., altered DNA methylation, histone modification) rather than direct coding mutations.

Conditions Associated with GAD1 Gene Mutations

The following conditions have been associated with mutations in the GAD1 gene:

Developmental and Epileptic Encephalopathy 89 (DEE89)

Developmental and Epileptic Encephalopathy 89 (DEE89) is a rare and severe genetic disorder that usually begins in early infancy. Babies with this condition often have seizures within the first few months of life, along with serious delays in learning, movement, and speech. 

Other signs may include low muscle tone, stiff limbs, and unusual facial features. 

DEE89 is caused by mutations in the GAD1 gene, which affects the production of GABA.

Neurodevelopmental Disorder with Progressive Spasticity and Brain White Matter Abnormalities (NEDSWMA)

Neurodevelopmental Disorder with Progressive Spasticity and Brain White Matter Abnormalities (NEDSWMA) is a rare, autosomal recessive condition characterized by early developmental delay, progressive microcephaly, hypotonia, and later-onset spasticity. 

Some individuals may show initial normal development followed by motor and cognitive skills regression. 

Brain imaging often reveals white matter abnormalities, including a thin corpus callosum. 

Mutations in the GAD1 gene, which disrupt GABA synthesis, have been implicated in a subset of cases, linking this disorder to other GABA-related neurodevelopmental syndromes.

Schizophrenia

Mutations in the GAD1 gene have been linked to schizophrenia. These mutations are associated with problems with memory, attention, and brain function, especially in the part of the brain that controls thinking and decision-making, the prefrontal cortex. 

People with schizophrenia often have lower levels of GAD1 activity in the prefrontal cortex. These effects may also be influenced by other genes, like COMT, which helps control dopamine, another important brain chemical.

Therapeutic Implications

Antipsychotics, such as clozapine, have been shown to increase GAD1 expression and improve chromatin regulation.

Targeted therapies, including epigenetic modifiers (CRISPR/Cas9, TALE), are under investigation to restore normal GAD1 expression.

When is GAD1 Genetic Analysis Relevant?

GAD1 genetic testing may be performed in the following scenarios:

Schizophrenia (SCZ)

Decreased GAD1 expression is a consistent finding in ~30% of patients, especially in the prefrontal cortex, and is linked to impaired inhibitory control.

Autism Spectrum Disorder (ASD)

GAD1 has been investigated for its potential role in altered GABAergic signaling seen in ASD.

Epigenetic dysregulation of GAD1 may arise during early neurodevelopment, providing support for the hypothesis that autism spectrum disorder originates, at least in part, from disruptions occurring during embryonic brain development.

Epilepsy

Particularly in early-onset developmental and epileptic encephalopathies (DEE), where impaired GABA synthesis is a suspected mechanism.

Anxiety Disorders

Altered GAD1 expression may contribute to anxiety and panic disorder via dysregulation of inhibitory circuits.

Test Procedure and Interpretation

Testing for GAD1 is performed as a genetic test to look for mutations in the gene that would alter functional protein availability. The following section outlines the testing procedures and interpretation.

Testing Procedure and Preparation

Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types. 

A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.

Normal Reference Ranges

Normal reference ranges for GAD1 genetic testing are considered to be without mutations that can alter the activity of the GAD1 proteins.

Clinical Implications of Positive GAD1 Mutations

The clinical implications of a positive GAD1 mutation test result will vary by individual. However, GAD1 mutations in symptomatic patients may signal a need for further assessment and possibly treatment, especially in the setting of epileptic or psychiatric symptoms.

Patients or practitioners with questions about the clinical implications of GAD1 mutations should seek further assessment with a genetic counselor or expert. 

What Does the Absence of GAD1 Genetic Variations Mean?

GAD1 test results must be interpreted in context, including environmental exposure, lifestyle, and clinical history. Alone, they cannot predict disease.

Key Takeaways for Clinicians

GAD1 is essential for GABA production and inhibitory neurotransmission.

Dysregulation is implicated in schizophrenia, epilepsy, and possibly ASD and anxiety disorders.

GAD1-based interventions represent a potential future therapeutic avenue but are not yet part of routine clinical care.

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.